Sun Yang, Yang Tingqi, Liu Xiaotong, Nie Jianqi, Jin Kuiqi, Li Hua, Zhou Pei, Xu Yinbiao, Liu Yupeng, Bai Zhonghu
A School of Life Sciences, Henan University, Kaifeng, China.
Henan Key Laboratory of Synthetic Biology and Biomanufacturing, Kaifeng, China.
Biotechnol J. 2025 Jun;20(6):e70053. doi: 10.1002/biot.70053.
Adeno-associated virus (AAV) vectors offer numerous advantages, including low immunogenicity and a high safety profile, but their development and wide application are still hindered by some technical limitations. Recent studies have shown that small molecule chemical additives can significantly increase the yield of rAAV vectors in HEK293. Our study found that the antimitotic nocodazole, a positive regulator of the rAAV genomic titer, approximately doubled the yield of rAAV vectors. In triple-transfected HEK293 suspension cells used for rAAV production, the addition of nocodazole caused the cells to arrest at G2/M phase. Compared to untreated cells, nocodazole-treated cells-initiated mitosis but were unable to undergo cytokinesis, resulting in prolonged mitotic arrest and apoptosis, this reduced the viable cell density at harvest. The final crude genomic vector titer of nocodazole-treated cultures was more than 1.7-fold higher than that of untreated controls. Optimal enhancement was observed when nocodazole was administered 2 hours post-transfection (hpt). Subsequent transcriptome analyses comparing cultures with and without nocodazole identified the key genes ZFP91 and SFRP5. Overexpression of ZFP91 and silencing of SFRP5 led to an increase in the G2/M phase arrested cells, reflecting the effect of nocodazole treatment. This delay in spindle formation increased packaging time and significantly increased rAAV vector yield by 2 to 3-fold. These findings highlight the potential for optimizing cellular conditions through small molecule additives and genetic modifications to overcome existing bottlenecks in AAV production.
腺相关病毒(AAV)载体具有诸多优势,包括低免疫原性和高安全性,但它们的开发和广泛应用仍受到一些技术限制的阻碍。最近的研究表明,小分子化学添加剂可显著提高HEK293细胞中重组腺相关病毒(rAAV)载体的产量。我们的研究发现,抗有丝分裂药物诺考达唑是rAAV基因组滴度的正调节剂,可使rAAV载体的产量增加近一倍。在用于生产rAAV的三重转染HEK293悬浮细胞中,添加诺考达唑会使细胞停滞在G2/M期。与未处理的细胞相比,经诺考达唑处理的细胞启动了有丝分裂,但无法进行胞质分裂,导致有丝分裂停滞延长和细胞凋亡,这降低了收获时的活细胞密度。经诺考达唑处理的培养物最终的粗基因组载体滴度比未处理的对照高1.7倍以上。在转染后2小时(hpt)给予诺考达唑时观察到最佳增强效果。随后对有或没有诺考达唑的培养物进行的转录组分析确定了关键基因ZFP91和SFRP5。ZFP91的过表达和SFRP5的沉默导致G2/M期停滞细胞增加,反映了诺考达唑处理的效果。纺锤体形成的这种延迟增加了包装时间,并使rAAV载体产量显著提高了2至3倍。这些发现突出了通过小分子添加剂和基因修饰优化细胞条件以克服AAV生产中现有瓶颈的潜力。